Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. More Details
Proven track record and fair value.
Share Price & News
How has Syneos Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SYNH has not had significant price volatility in the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: SYNH underperformed the US Life Sciences industry which returned 49.7% over the past year.
Return vs Market: SYNH underperformed the US Market which returned 19.5% over the past year.
Price Volatility Vs. Market
How volatile is Syneos Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StAre Syneos Health's (NASDAQ:SYNH) Statutory Earnings A Good Guide To Its Underlying Profitability?
2 weeks ago | Simply Wall StA Look At The Intrinsic Value Of Syneos Health, Inc. (NASDAQ:SYNH)
1 month ago | Simply Wall StOur View On Syneos Health's (NASDAQ:SYNH) CEO Pay
Is Syneos Health undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SYNH ($59.7) is trading below our estimate of fair value ($62.97)
Significantly Below Fair Value: SYNH is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: SYNH is good value based on its PE Ratio (33.1x) compared to the US Life Sciences industry average (44.9x).
PE vs Market: SYNH is poor value based on its PE Ratio (33.1x) compared to the US market (19x).
Price to Earnings Growth Ratio
PEG Ratio: SYNH is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: SYNH is good value based on its PB Ratio (2.1x) compared to the US Life Sciences industry average (7x).
How is Syneos Health forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SYNH's forecast earnings growth (23.6% per year) is above the savings rate (2.2%).
Earnings vs Market: SYNH's earnings (23.6% per year) are forecast to grow faster than the US market (22.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SYNH's revenue (6.8% per year) is forecast to grow slower than the US market (10% per year).
High Growth Revenue: SYNH's revenue (6.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SYNH's Return on Equity is forecast to be low in 3 years time (12.5%).
How has Syneos Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SYNH has a large one-off loss of $65.9M impacting its June 30 2020 financial results.
Growing Profit Margin: SYNH's current net profit margins (4.1%) are higher than last year (0.4%).
Past Earnings Growth Analysis
Earnings Trend: SYNH's earnings have grown by 3.8% per year over the past 5 years.
Accelerating Growth: SYNH's earnings growth over the past year (982.5%) exceeds its 5-year average (3.8% per year).
Earnings vs Industry: SYNH earnings growth over the past year (982.5%) exceeded the Life Sciences industry 14.9%.
Return on Equity
High ROE: SYNH's Return on Equity (6.2%) is considered low.
How is Syneos Health's financial position?
Financial Position Analysis
Short Term Liabilities: SYNH's short term assets ($1.6B) exceed its short term liabilities ($1.4B).
Long Term Liabilities: SYNH's short term assets ($1.6B) do not cover its long term liabilities ($3.0B).
Debt to Equity History and Analysis
Debt Level: SYNH's debt to equity ratio (92.6%) is considered high.
Reducing Debt: SYNH's debt to equity ratio has reduced from 166.9% to 92.6% over the past 5 years.
Debt Coverage: SYNH's debt is not well covered by operating cash flow (14.1%).
Interest Coverage: SYNH's interest payments on its debt are well covered by EBIT (3x coverage).
What is Syneos Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SYNH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SYNH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SYNH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SYNH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SYNH's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Alistair Macdonald (50 yo)
Mr. Alistair Macdonald has been the Chief Executive Officer and Director of Syneos Health, Inc. (formerly, INC Research Holdings, Inc.) since October 1, 2016. Mr. Macdonald served as the Chief Operating Of ...
CEO Compensation Analysis
Compensation vs Market: Alistair's total compensation ($USD7.65M) is about average for companies of similar size in the US market ($USD7.31M).
Compensation vs Earnings: Alistair's compensation has been consistent with company performance over the past year.
|CEO & Director||4yrs||US$7.65m||0.11% |
|Chief Financial Officer||2.17yrs||US$2.25m||0.029% |
|General Counsel & Corporate Secretary||1.92yrs||US$1.73m||0.0053% |
|President of Commercial Solutions||2.83yrs||US$2.04m||0.011% |
|President of Clinical Solutions||1.83yrs||US$2.07m||0.0046% |
|Executive VP & Chief Accounting Officer||1.92yrs||no data||0.012% |
|Chief Scientific Officer||4.58yrs||no data||no data|
|Senior Vice President of Investor Relations||no data||no data||no data|
|Global Head of Corporate Communications & Marketing||3.17yrs||no data||no data|
|Chief Human Resources Officer||no data||no data||no data|
|Chief Business Officer||4.67yrs||no data||no data|
|Executive VP of Clinical Development for General Medicine & GM||5.17yrs||no data||no data|
Experienced Management: SYNH's management team is considered experienced (3 years average tenure).
|CEO & Director||4yrs||US$7.65m||0.11% |
|Independent Director||3.17yrs||US$255.00k||no data|
|Independent Director||4yrs||US$275.00k||0.012% |
|Independent Director||3.58yrs||US$269.75k||0.011% |
|Independent Director||3.58yrs||US$278.50k||0.011% |
|Independent Director||3.17yrs||US$82.75k||no data|
|Independent Director||3.17yrs||US$257.75k||no data|
|Independent Director||4yrs||US$267.00k||0.012% |
|Independent Director||3.17yrs||US$90.00k||no data|
|Independent Chairman||1.83yrs||US$375.00k||0.014% |
|Independent Director||0.92yr||US$113.20k||0.0018% |
Experienced Board: SYNH's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Syneos Health, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Syneos Health, Inc.
- Ticker: SYNH
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$6.207b
- Shares outstanding: 103.97m
- Website: https://www.syneoshealth.com
Number of Employees
- Syneos Health, Inc.
- 1030 Sync Street
- North Carolina
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SYNH||NasdaqGS (Nasdaq Global Select)||Yes||New Class A Common Stock||US||USD||Nov 2014|
|8IN||DB (Deutsche Boerse AG)||Yes||New Class A Common Stock||DE||EUR||Nov 2014|
Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, C ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/20 00:52|
|End of Day Share Price||2020/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.